AVTX vs INCY
AVTX: Clinical-stage biotech developing abdakibart, a humanized anti-IL-1β antibody for hidradenitis suppurativa with Phase 2 data readout expected mid-2026. INCY: A biopharmaceutical company pioneering targeted therapies for blood cancers and inflammatory diseases, with flagship JAK inhibitor JAKAFI generating substantial cash flow.
Side-by-side fundamentals
| Metric | AVTX | INCY | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $18.15 | $115.79 | |
| Market cap as of 2026-07-23 | $961M | $23.3B | |
| P/E as of 2026-07-23 | n/a | 16.29 | |
| PEG as of 2026-07-23 | n/a | 1.00 | |
| Net margin as of 2026-07-23 | -23254.2% | +26.7% | INCY higher |
| Gross margin as of 2026-07-23 | +242.2% | +93.0% | AVTX higher |
| Operating margin as of 2026-07-23 | -33461.0% | +30.1% | INCY higher |
| ROE as of 2026-07-23 | -77.8% | +29.2% | INCY higher |
| ROA as of 2026-07-23 | -61.7% | +21.6% | INCY higher |
| Debt / equity as of 2026-07-23 | 0.03 | 0.01 | INCY lower |
| Revenue growth (YoY) as of 2026-07-23 | -86.6% | +21.5% | INCY higher |
| Revenue CAGR (3y) SEC XBRL | -85.2% | +14.8% | INCY higher |
| Beta as of 2026-07-23 | 0.75 | 0.77 | |
| 1-year return as of 2026-07-22 close | +182.7% | +74.2% | AVTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.